157 related articles for article (PubMed ID: 34152837)
1. Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials.
DuBois SG; Bagatell R
J Clin Oncol; 2021 Aug; 39(23):2525-2527. PubMed ID: 34152837
[No Abstract] [Full Text] [Related]
2. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2010 May; (5):CD006301. PubMed ID: 20464740
[TBL] [Abstract][Full Text] [Related]
3. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.
Peinemann F; Tushabe DA; van Dalen EC; Berthold F
Cochrane Database Syst Rev; 2015 May; 2015(5):CD010774. PubMed ID: 25989478
[TBL] [Abstract][Full Text] [Related]
4. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; van Dalen EC
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD006301. PubMed ID: 26436598
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.
Yalçin B; Kremer LC; Caron HN; van Dalen EC
Cochrane Database Syst Rev; 2013 Aug; (8):CD006301. PubMed ID: 23970444
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid postconsolidation therapy for high-risk neuroblastoma patients treated with autologous haematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Enk H; Berthold F
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD010685. PubMed ID: 28840597
[TBL] [Abstract][Full Text] [Related]
7. Retinoic acid post consolidation therapy for high-risk neuroblastoma patients treated with autologous hematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Tushabe DA; Berthold F
Cochrane Database Syst Rev; 2015 Jan; 1():CD010685. PubMed ID: 25634649
[TBL] [Abstract][Full Text] [Related]
8. Anti-GD2 antibody-containing immunotherapy postconsolidation therapy for people with high-risk neuroblastoma treated with autologous haematopoietic stem cell transplantation.
Peinemann F; van Dalen EC; Enk H; Tytgat GA
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012442. PubMed ID: 31016728
[TBL] [Abstract][Full Text] [Related]
9. Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatments.
Korn EL; Freidlin B
J Clin Oncol; 2010 Aug; 28(24):3800-2. PubMed ID: 20660828
[No Abstract] [Full Text] [Related]
10. Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma.
Bona K; Li Y; Winestone LE; Getz KD; Huang YS; Fisher BT; Desai AV; Richardson T; Hall M; Naranjo A; Henderson TO; Aplenc R; Bagatell R
J Natl Cancer Inst; 2021 Mar; 113(3):282-291. PubMed ID: 33227816
[TBL] [Abstract][Full Text] [Related]
11. Retinoic Acid for High-risk Neuroblastoma Patients after Autologous Stem Cell Transplantation - Cochrane Review.
Peinemann F; van Dalen EC; Berthold F
Klin Padiatr; 2016 Apr; 228(3):124-9. PubMed ID: 27011226
[TBL] [Abstract][Full Text] [Related]
12. The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy.
Secola R; Marachelian A; Cohn SL; Toy B; Neville K; Granger M; Brentlinger A; Martin G
J Pediatr Oncol Nurs; 2017; 34(3):160-172. PubMed ID: 28061552
[TBL] [Abstract][Full Text] [Related]
13. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
[TBL] [Abstract][Full Text] [Related]
14. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD010885. PubMed ID: 29975402
[TBL] [Abstract][Full Text] [Related]
15. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2016 Aug; (8):CD010885. PubMed ID: 27498707
[TBL] [Abstract][Full Text] [Related]
16. Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.
Peinemann F; van Dalen EC; Berthold F
Klin Padiatr; 2016 Apr; 228(3):130-4. PubMed ID: 27043079
[TBL] [Abstract][Full Text] [Related]
17. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jun; (6):CD010885. PubMed ID: 24968257
[TBL] [Abstract][Full Text] [Related]
18. Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.
Reynolds CP
Curr Oncol Rep; 2000 Nov; 2(6):511-8. PubMed ID: 11122886
[TBL] [Abstract][Full Text] [Related]
19. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized controlled trial.
Wagner LM; Billups CA; Furman WL; Rao BN; Santana VM
J Clin Oncol; 2004 May; 22(10):1886-93. PubMed ID: 15143081
[TBL] [Abstract][Full Text] [Related]
20. Can EPO reduce blood transfusion requirements during induction therapy for high-risk neuroblastoma?
Cazzola M
Nat Clin Pract Oncol; 2004 Nov; 1(1):22-3. PubMed ID: 16264794
[No Abstract] [Full Text] [Related]
[Next] [New Search]